Current and future use of favipiravir in patients with COVID-19
There are experimental and clinical data regarding the activity of favipiravir against the SARS-CoV-2 virus. The is evidence of significant variability in pharmacokinetics and associated achievement of the required inhibitory concentration of the drug. The evidence base for the effectiveness of use...
Gorde:
| Egile Nagusiak: | , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Russo |
| Argitaratua: |
Izdatelstvo OKI
2020-10-01
|
| Saila: | Качественная клиническая практика |
| Gaiak: | |
| Sarrera elektronikoa: | https://www.clinvest.ru/jour/article/view/540 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|